<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759290</url>
  </required_header>
  <id_info>
    <org_study_id>12-302</org_study_id>
    <nct_id>NCT01759290</nct_id>
  </id_info>
  <brief_title>ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.</brief_title>
  <official_title>ABSORB FIRST Registry: An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABSORB FIRST is a prospective, multi-center registry. The objectives of the study are to:

        -  Provide ongoing post-market surveillance for documentation of safety, performance and
           clinical outcomes of the Absorb BVS (Bioresorbable Vascular Scaffold) System in daily
           percutaneous coronary intervention (PCI) practice per Instructions for Use (IFU,
           on-label use).

        -  To evaluate the safety and performance of 12 mm or shorter Absorb BVS in single or
           overlapping use (bailout, optimization of long lesion treatment) for the treatment of
           patients with ischemic heart disease caused by de novo native coronary artery lesion(s)

        -  Collect additional information (e.g. acute success) to evaluate handling and
           implantation of Absorb BVS by physicians under a wide range of commercial use conditions
           and following routine clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the ABSORB FIRST Registry is intended to provide an assessment of the safety and performance
      of the Absorb BVS device in accordance to the IFU in real world use involving more complex
      patients, lesions and use (examples: longer lesions, overlapping use, bailout, patients at
      high risks for cardiac events, etc.).

      The ABSORB FIRST study will register a minimum of 1800 patients in approximately 90 sites
      throughout multiple countries worldwide where Absorb BVS has regulatory approval or is
      commercially available.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Success: Clinical Device Success (Lesion Level Analysis)</measure>
    <time_frame>&lt; or = 1 day</time_frame>
    <description>Device success was defined as the achievement of a final in-scaffold residual diameter stenosis of &lt;50% assessed by online quantitative angiography or visual estimation, using Absorb BVS and without a device deficiency. A device was considered to have failed if it did not meet the requirements of the definition for clinical device success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Success: Clinical Procedure Success (Per Subject Analysis)</measure>
    <time_frame>During the hospital stay with a maximum of 3 days post index procedure</time_frame>
    <description>Procedure success was defined as the achievement of a final in-scaffold diameter stenosis of &lt;50% by online quantitative coronary angiography (QCA) or visual estimation using Absorb BVS, with or without any adjunctive devices, and without the occurrence of cardiac death, target vessel MI (Q-wave and non-Q-wave MI), or repeat revascularization of the target lesion within 3 days of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Scaffold Thrombosis</measure>
    <time_frame>&lt;1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subacute ScaffoldThrombosis</measure>
    <time_frame>1 to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Scaffold Thrombosis</measure>
    <time_frame>31 to 365 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death, All MI, All Revascularization (DMR)</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death, All MI, All Revascularization (DMR)</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 - 37 Days</time_frame>
    <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</measure>
    <time_frame>0 to 37 Days</time_frame>
    <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI</measure>
    <time_frame>0 to 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death, All MI, All Revascularization (DMR)</measure>
    <time_frame>0 to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 180 Days</time_frame>
    <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</measure>
    <time_frame>0 to 180 Days</time_frame>
    <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>0 to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI</measure>
    <time_frame>0 to 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death, All MI, All Revascularization (DMR)</measure>
    <time_frame>0 to 407 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>0 to 407 Days</time_frame>
    <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death/All MI</measure>
    <time_frame>0 to 407 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Death/All MI</measure>
    <time_frame>0 to 407 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Cardiovascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR): All TLR</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR): All TVR</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization</measure>
    <time_frame>0 to 7 days (In-hospital)</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Cardiovascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR): All TLR</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR): All TVR</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization</measure>
    <time_frame>0 to 37 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Cardiovascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR): All TLR</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR): All TVR</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization</measure>
    <time_frame>0 to 180 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (Cardiovascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR): All TLR</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR): All TVR</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization</measure>
    <time_frame>0 to 407 days</time_frame>
    <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1800</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <condition>Coronary Occlusion</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Restenosis</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Absorb Bioresorbable Vascular Scaffold</arm_group_label>
    <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Absorb Bioresorbable Vascular Scaffold</intervention_name>
    <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
    <arm_group_label>Absorb Bioresorbable Vascular Scaffold</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled into this registry will be male and female patients derived from the
        general interventional cardiology population who satisfy the inclusion and exclusion
        criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria must follow the most recent IFU which may include but are not
             limited to the following:

               -  Patient must be at least 18 years of age at the time of signing the Informed
                  Consent Form

               -  Patient is to be treated for de novo lesions located in previously untreated
                  vessels.

               -  Patient must agree to undergo all required follow-up visits and data collection.

        Exclusion Criteria:

          -  The exclusion criteria must follow the most recent IFU which may include but are not
             limited to the following:

               -  Inability to obtain a signed informed consent from potential patient.

               -  Patient belongs to a vulnerable population (per investigator's judgment, this
                  also includes people with a direct link (hierarchical or financial benefit) to
                  the registry Doctor or the registry Sponsor).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashok Seth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Escorts Heart Institute, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Eeckhout, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Staehr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Vascular</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivian Mao, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular International BVBA</name>
      <address>
        <city>Brussels</city>
        <zip>0886.537.933</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <results_first_submitted>August 26, 2016</results_first_submitted>
  <results_first_submitted_qc>August 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2016</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioplasty</keyword>
  <keyword>Bioabsorbable</keyword>
  <keyword>Bioresorbable</keyword>
  <keyword>BVS</keyword>
  <keyword>Coronary Artery Endothelial Responsiveness</keyword>
  <keyword>Coronary Scaffold</keyword>
  <keyword>Coronary Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1800 subjects were enrolled at 87 outside US (OUS) study sites across 21 counties worldwide. The first patient registered on January 21, 2013. The patient registration was complete on Aug 30, 2014, and the last patient completed the 1-year clinical follow-up on Sep 09, 2015. The database has been closed on Oct 30, 2015.</recruitment_details>
      <pre_assignment_details>A total of 81 subjects are discontinued from the study population (1800) due to death:17, withdrawal of consent:5, withdrawn by physician:2, loss to follow-up:53 and unknown reasons:4. A total of 28 subjects with MI/revascularization events or reached 1-year follow-up window were included in the clinical outcome analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb Bioresorbable Vascular Scaffold</title>
          <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1800"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1719"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subjects withdrawn consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb Bioresorbable Vascular Scaffold</title>
          <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Arab Emirates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saudi Arabia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jordan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bahrain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vietnam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
        <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
          <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.11" upper_limit="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success: Clinical Device Success (Lesion Level Analysis)</title>
        <description>Device success was defined as the achievement of a final in-scaffold residual diameter stenosis of &lt;50% assessed by online quantitative angiography or visual estimation, using Absorb BVS and without a device deficiency. A device was considered to have failed if it did not meet the requirements of the definition for clinical device success.</description>
        <time_frame>&lt; or = 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success: Clinical Device Success (Lesion Level Analysis)</title>
          <description>Device success was defined as the achievement of a final in-scaffold residual diameter stenosis of &lt;50% assessed by online quantitative angiography or visual estimation, using Absorb BVS and without a device deficiency. A device was considered to have failed if it did not meet the requirements of the definition for clinical device success.</description>
          <units>percentage of lesions</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1800"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Target Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="97.30" upper_limit="98.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Success: Clinical Procedure Success (Per Subject Analysis)</title>
        <description>Procedure success was defined as the achievement of a final in-scaffold diameter stenosis of &lt;50% by online quantitative coronary angiography (QCA) or visual estimation using Absorb BVS, with or without any adjunctive devices, and without the occurrence of cardiac death, target vessel MI (Q-wave and non-Q-wave MI), or repeat revascularization of the target lesion within 3 days of the index procedure.</description>
        <time_frame>During the hospital stay with a maximum of 3 days post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Success: Clinical Procedure Success (Per Subject Analysis)</title>
          <description>Procedure success was defined as the achievement of a final in-scaffold diameter stenosis of &lt;50% by online quantitative coronary angiography (QCA) or visual estimation using Absorb BVS, with or without any adjunctive devices, and without the occurrence of cardiac death, target vessel MI (Q-wave and non-Q-wave MI), or repeat revascularization of the target lesion within 3 days of the index procedure.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="96.10" upper_limit="97.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Scaffold Thrombosis</title>
        <time_frame>&lt;1 day</time_frame>
        <population>Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Scaffold Thrombosis</title>
          <population>Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Scaffold Thrombosis event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1770"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subacute ScaffoldThrombosis</title>
        <time_frame>1 to 30 days</time_frame>
        <population>Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Subacute ScaffoldThrombosis</title>
          <population>Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Scaffold Thrombosis event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1770"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Scaffold Thrombosis</title>
        <time_frame>31 to 365 Days</time_frame>
        <population>Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Scaffold Thrombosis event.</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Late Scaffold Thrombosis</title>
          <population>Analysis population excludes subjects who are truly lost-to-follow-up, defined as subjects who are terminated through a given time point without any Scaffold Thrombosis event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1756"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death, All MI, All Revascularization (DMR)</title>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death, All MI, All Revascularization (DMR)</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.33" upper_limit="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.56" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (MACE)</title>
        <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (MACE)</title>
          <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.52" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
        <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
          <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.43" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.43" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI</title>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.43" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death, All MI, All Revascularization (DMR)</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death, All MI, All Revascularization (DMR)</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.30" upper_limit="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.87" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (MACE)</title>
        <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 - 37 Days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (MACE)</title>
          <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.78" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
        <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 37 Days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
          <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.65" upper_limit="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.69" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI</title>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.69" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death, All MI, All Revascularization (DMR)</title>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death, All MI, All Revascularization (DMR)</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.40" upper_limit="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.06" upper_limit="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (MACE)</title>
        <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 180 Days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (MACE)</title>
          <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.77" upper_limit="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
        <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 180 Days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/TV-MI/ID-TLR (Target Lesion Failure (TLF))</title>
          <description>Target Lesion Failure includes Cardiac Death,Target Vessel-Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.53" upper_limit="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.29" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI</title>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.43" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death, All MI, All Revascularization (DMR)</title>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death, All MI, All Revascularization (DMR)</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="7.14" upper_limit="9.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
        <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI/ID-TVR (Target Vessel Failure (TVF)</title>
          <description>Target Vessel Failure (TVF) includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Vessel Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.86" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Event (MACE)</title>
        <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
        <time_frame>0 to 407 Days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Event (MACE)</title>
          <description>MACE includes Cardiac Death, All Myocardial Infarction and Ischemic Driven-Target Lesion Revascularization. This is one of the Composite Clinical Endpoints (Safety and Efficacy, hierarchical).</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.36" upper_limit="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death/All MI</title>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.48" upper_limit="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Death/All MI</title>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Death/All MI</title>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.67" upper_limit="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Cardiovascular, Non-Cardiovascular)</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Cardiovascular, Non-Cardiovascular)</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.01" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.35" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR): All TLR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR): All TLR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.16" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.16" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR): All TVR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR): All TVR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.20" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.20" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 7 days (In-hospital)</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.92" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Cardiovascular, Non-Cardiovascular)</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Cardiovascular, Non-Cardiovascular)</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.01" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.60" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR): All TLR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR): All TLR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.31" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.31" upper_limit="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR): All TVR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR): All TVR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.47" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.43" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 37 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1771"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.86" upper_limit="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Cardiovascular, Non-Cardiovascular)</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Cardiovascular, Non-Cardiovascular)</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.39" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.83" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR): All TLR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR): All TLR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.83" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.83" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR): All TVR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR): All TVR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.34" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.19" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 180 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1768"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.47" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Cardiovascular, Non-Cardiovascular)</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Cardiovascular, Non-Cardiovascular)</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.56" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
        <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Myocardial Infarction (MI): Q-wave MI (QMI) and Non-QMI (NQMI), TV, and Non-TV (NTV).</title>
          <description>This is one of the Safety Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.92" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR): All TLR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR): All TLR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.43" upper_limit="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization : Ischemia-Driven (ID-TLR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.29" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR): All TVR</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR): All TVR</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.21" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization : Ischemic-driven (ID-TVR)</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.87" upper_limit="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization</title>
        <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
        <time_frame>0 to 407 days</time_frame>
        <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb Bioresorbable Vascular Scaffold</title>
            <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization</title>
          <description>This is one of the Efficacy Component (non-hierarchical) endpoints.</description>
          <population>Subjects are only counted once for each type of event in each time period.The denominators used in the calculations determined according to the analysis population with excluding subjects who are lost to follow-up through given timepoint without any DMR event (all death, all MI per Protocol definition, all revascularization, respectively).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1764"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="6.09" upper_limit="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb Bioresorbable Vascular Scaffold</title>
          <description>Subjects receiving the Absorb Bioresorbable Vascular Scaffold</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="249" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="52" subjects_affected="47" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Primary amyloidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Exercise electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Stress echocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="395" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="76" subjects_affected="69" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Primary amyloidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac function disturbance postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Exercise electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Stress echocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Personality disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1800"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kunal Sampat</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>408-845-0746</phone>
      <email>kunal.sampat@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

